Zymeworks (ZYME) Other Non-Current Liabilities (2021 - 2026)
Zymeworks recorded quarterly Other Non-Current Liabilities of $278000.0 in Q1 2026, little changed quarter-over-quarter from $278000.0 in Q4 2025, and down 67.52% year-over-year from $856000.0 in Q1 2025.
Zymeworks' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $278000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 67.52% year-over-year to $278000.0; the TTM figure through Mar 2026 stood at $278000.0 (down 67.52% YoY), while the FY2025 annual figure was $278000.0, down 69.88% from the prior year.
- Other Non-Current Liabilities came in at $278000.0 for Q1 2026 at Zymeworks, roughly flat from $278000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $2.9 million in Q3 2022 to a low of $278000.0 in Q3 2025.
- A 5-year average of $1.1 million and a median of $929000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities plunged 90.01% in 2023 and soared 217.06% in 2024, its largest moves.
- Zymeworks' Other Non-Current Liabilities stood at $1.6 million in 2022, then increased by 3.59% to $1.7 million in 2023, then tumbled by 45.74% to $923000.0 in 2024, then plunged by 69.88% to $278000.0 in 2025, then changed by 0.0% to $278000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $278000.0, $278000.0, and $278000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 278,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 828,000.00 |
| Mar 31, 2025 | 856,000.00 |
| Dec 31, 2024 | 923,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 293,000.00 |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 2.93 Mn |
| Dec 31, 2021 | 2.75 Mn |